SurrozenSRZN
About: Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Employees: 42
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
61% more capital invested
Capital invested by funds: $15.6M [Q1] → $25.1M (+$9.55M) [Q2]
31% more funds holding
Funds holding: 16 [Q1] → 21 (+5) [Q2]
22.99% more ownership
Funds ownership: 48.65% [Q1] → 71.64% (+22.99%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for SRZN.